Hedge Fund - Redmile Group
Fate Therapeutics Inc (FATE)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2023 - Q4 (2023-12-31) | $49,252,273 | 1.76% | 13,169,057 | $2.36 |
| 2 | 2023 - Q3 (2023-09-30) | $27,823,785 | 1.32% | 13,124,427 | $3.31 |
| 3 | 2023 - Q2 (2023-06-30) | $62,472,273 | 2.39% | 13,124,427 | $5.52 |
| 4 | 2023 - Q1 (2023-03-31) | $73,856,165 | 3.2% | 12,957,222 | $6.03 |
| 5 | 2022 - Q4 (2022-12-31) | $130,738,370 | 5.34% | 12,957,222 | $18.78 |
| 6 | 2022 - Q3 (2022-09-30) | $290,371,000 | 11.26% | 12,957,222 | $28.89 |
| 7 | 2022 - Q2 (2022-06-30) | $321,080,000 | 12.26% | 12,957,222 | $27.59 |
| 8 | 2022 - Q1 (2022-03-31) | $502,351,000 | 15.68% | 12,957,222 | $38.72 |
| 9 | 2021 - Q4 (2021-12-31) | $758,127,000 | 17.23% | 12,957,222 | $56.68 |
| 10 | 2021 - Q3 (2021-09-30) | $767,975,000 | 13.39% | 12,957,222 | $78.44 |
| 11 | 2021 - Q2 (2021-06-30) | $1,124,557,000 | 16.64% | 12,957,222 | $80.58 |
| 12 | 2021 - Q1 (2021-03-31) | $1,068,323,000 | 15.04% | 12,957,222 | $95.82 |
| 13 | 2020 - Q4 (2020-12-31) | $1,148,422,000 | 13.9% | 12,629,737 | $62.10 |
| 14 | 2020 - Q3 (2020-09-30) | $504,811,000 | 9.26% | 12,629,737 | $34.92 |
| 15 | 2020 - Q2 (2020-06-30) | $433,326,000 | 7.99% | 12,629,737 | $29.80 |
| 16 | 2020 - Q1 (2020-03-31) | $249,125,000 | 6.98% | 11,216,809 | $25.29 |
| 17 | 2019 - Q4 (2019-12-31) | $219,513,000 | 5.25% | 11,216,809 | $15.88 |
| 18 | 2019 - Q3 (2019-09-30) | $174,197,000 | 5.82% | 11,216,809 | $19.17 |
| 19 | 2019 - Q2 (2019-06-30) | $210,301,000 | 5.95% | 10,359,666 | $18.02 |
| 20 | 2019 - Q1 (2019-03-31) | $182,019,000 | 5.32% | 10,359,666 | $15.78 |
| 21 | 2018 - Q4 (2018-12-31) | $132,915,000 | 5.34% | 10,359,666 | $13.94 |
| 22 | 2018 - Q3 (2018-09-30) | $168,759,000 | 5.19% | 10,359,666 | $11.83 |
| 23 | 2018 - Q2 (2018-06-30) | $75,479,000 | 2.56% | 6,655,962 | $11.02 |
| 24 | 2018 - Q1 (2018-03-31) | $64,962,000 | 2.5% | 6,655,962 | $9.58 |
| 25 | 2017 - Q4 (2017-12-31) | $33,394,000 | 1.45% | 5,465,486 | $4.46 |
| 26 | 2017 - Q3 (2017-09-30) | $5,619,000 | 0.27% | 1,419,058 | $3.40 |
| 27 | 2017 - Q2 (2017-06-30) | $4,598,000 | 0.27% | 1,419,058 | $3.83 |
| 28 | 2017 - Q1 (2017-03-31) | $6,457,000 | 0.41% | 1,419,058 | $3.66 |
| 29 | 2016 - Q4 (2016-12-31) | $3,562,000 | 0.3% | 1,419,058 | $2.68 |
| 30 | 2016 - Q3 (2016-09-30) | $4,446,000 | 0.35% | 1,425,158 | $2.43 |
| 31 | 2016 - Q2 (2016-06-30) | $2,554,000 | 0.24% | 1,502,180 | $1.81 |
| 32 | 2016 - Q1 (2016-03-31) | $2,677,000 | 0.27% | 1,486,980 | $2.06 |
| 33 | 2015 - Q4 (2015-12-31) | $7,990,000 | 0.59% | 2,371,001 | $4.20 |
| 34 | 2015 - Q3 (2015-09-30) | $11,059,000 | 0.25% | 2,074,836 | $6.83 |
| 35 | 2015 - Q2 (2015-06-30) | $12,988,000 | 1.06% | 2,007,446 | $5.98 |
The displayed share prices are average quarterly stock market prices.